Biotech News

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva (INVA)Innoviva2026-06-25 13:46 ESTClinical readout

Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria gonorrhoeae WALTHAM, Mass. --(BUSINESS WIRE)--Oct.

Open original release

Related news

INVAInnoviva2026-06-25 13:46 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

INVAInnoviva2026-06-25 13:46 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-06-25 13:46 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

INVAInnoviva2026-06-25 13:46 EST

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-25 13:46 EST

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

INVAInnoviva2026-06-25 13:46 EST

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

View all latest news

Innoviva

Innoviva is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

INVAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

INVAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

INVABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

INVAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

INVAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 22.21 USD
Market cap: 1.64B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States